NASDAQ:GNLX Genelux (GNLX) Stock Forecast, Price & News $26.88 -0.72 (-2.61%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$26.01▼$28.1250-Day Range$20.27▼$29.9852-Week Range$5.35▼$40.98Volume109,021 shsAverage Volume394,489 shsMarket Capitalization$663.13 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Genelux MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.0% Downside$25.00 Price TargetShort InterestHealthy0.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.42Based on 17 Articles This WeekInsider TradingSelling Shares$4.45 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.94) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.26 out of 5 starsMedical Sector927th out of 968 stocksPharmaceutical Preparations Industry425th out of 439 stocks 1.5 Analyst's Opinion Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.00, Genelux has a forecasted downside of 7.0% from its current price of $26.88.Amount of Analyst CoverageGenelux has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.93% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genelux has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNLX. Previous Next 0.9 News and Social Media Coverage News SentimentGenelux has a news sentiment score of -0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Genelux this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GNLX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,451,537.00 in company stock.Percentage Held by Insiders11.70% of the stock of Genelux is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.77% of the stock of Genelux is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genelux are expected to grow in the coming year, from ($0.94) to ($0.58) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Genelux (NASDAQ:GNLX) StockGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.Read More GNLX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNLX Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comGenelux Co. (NASDAQ:GNLX) Major Shareholder Sells $705,500.68 in StockSeptember 22, 2023 | americanbankingnews.comGenelux (NASDAQ:GNLX) Trading Down 6% After Insider SellingSeptember 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 21, 2023 | benzinga.com10% Owner At This Health Care Company Sells $1.56M of StockSeptember 19, 2023 | finance.yahoo.comDirector John Thomas Sells 6667 Shares of Genelux Corp (GNLX)September 19, 2023 | benzinga.comGenelux Director Trades Company's StockSeptember 19, 2023 | americanbankingnews.comGenelux Co. (NASDAQ:GNLX) VP Sells $227,656.00 in StockSeptember 19, 2023 | americanbankingnews.comGenelux (NASDAQ:GNLX) Shares Gap Down Following Insider SellingSeptember 23, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 18, 2023 | americanbankingnews.comGenelux Co. (NASDAQ:GNLX) VP Sells $629,972.00 in StockSeptember 18, 2023 | americanbankingnews.comGenelux Co. (NASDAQ:GNLX) Major Shareholder Sells $408,046.08 in StockSeptember 17, 2023 | americanbankingnews.comGenelux (NASDAQ:GNLX) Stock Price Down 3.3% Following Insider SellingSeptember 15, 2023 | finance.yahoo.comDirector John Smither Sells 900 Shares of Genelux Corp (GNLX)September 14, 2023 | benzinga.comGenelux 10% Owner Sold $1.17M In Company StockSeptember 14, 2023 | finance.yahoo.com10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX)September 14, 2023 | finance.yahoo.comGenelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 13, 2023 | americanbankingnews.comGenelux (NASDAQ:GNLX) Coverage Initiated by Analysts at Maxim GroupSeptember 12, 2023 | benzinga.comGenelux 10% Owner Trades $878K In Company StockSeptember 12, 2023 | msn.comMaxim Group Initiates Coverage of Genelux (GNLX) with Buy RecommendationSeptember 7, 2023 | finance.yahoo.comGenelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceAugust 31, 2023 | finance.yahoo.comGenelux (NASDAQ:GNLX) Is In A Good Position To Deliver On Growth PlansAugust 30, 2023 | seekingalpha.comGenelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage TestingAugust 28, 2023 | markets.businessinsider.comGenelux Appoints Lourie Zak As New CFOAugust 28, 2023 | msn.comGenelux gets new finance chiefAugust 28, 2023 | finance.yahoo.comGenelux Corporation Announces New Chief Financial OfficerAugust 14, 2023 | finance.yahoo.comGenelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesAugust 3, 2023 | finance.yahoo.comGenelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023See More Headlines Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address GNLX Company Calendar Last Earnings8/14/2023Today9/22/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.00 High Stock Price Forecast$40.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside-7.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.64 Quick Ratio3.64 Sales & Book Value Annual Sales$11.07 million Price / Sales59.90 Cash FlowN/A Price / Cash FlowN/A Book Value($1.51) per share Price / Book-17.80Miscellaneous Outstanding Shares24,670,000Free Float21,784,000Market Cap$663.13 million OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Thomas Zindrick J.D. (Age 64)Chairman, CEO & Pres Comp: $500kMr. Sean Ryder J.D. (Age 54)Gen. Counsel & Corp. Sec. Comp: $380kMs. Lourie S. Zak (Age 60)CFO & Principal Accounting Officer Dr. Joseph Cappello Ph.D. (Age 66)Chief Technical Officer Dr. Yong Yu Ph.D. (Age 52)Sr. VP of Clinical Devel. Prof. Paul Scigalla M.D. (Age 77)Ph.D., Chief Medical Officer Mr. Ralph Smalling B.Sc. (Age 67)Head of Regulatory Affairs Ms. Caroline Jewett (Age 59)Head of Quality More ExecutivesKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTCentessa PharmaceuticalsNASDAQ:CNTAKura OncologyNASDAQ:KURATyra BiosciencesNASDAQ:TYRAARS PharmaceuticalsNASDAQ:SPRYView All CompetitorsInsiders & InstitutionsYong YuSold 6,000 sharesTotal: $167,760.00 ($27.96/share)Sean RyderSold 10,000 sharesTotal: $300,000.00 ($30.00/share)John ThomasSold 3,334 sharesTotal: $83,316.66 ($24.99/share)Aladar SzalaySold 30,292 sharesTotal: $705,500.68 ($23.29/share)Yong YuSold 10,400 sharesTotal: $227,656.00 ($21.89/share)View All Insider TransactionsView All Institutional Transactions GNLX Stock - Frequently Asked Questions Should I buy or sell Genelux stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNLX shares. View GNLX analyst ratings or view top-rated stocks. What is Genelux's stock price forecast for 2023? 2 Wall Street research analysts have issued 12-month target prices for Genelux's shares. Their GNLX share price forecasts range from $10.00 to $40.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests that the stock has a possible downside of 7.0%. View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts. How have GNLX shares performed in 2023? Genelux's stock was trading at $6.01 on January 1st, 2023. Since then, GNLX stock has increased by 347.3% and is now trading at $26.88. View the best growth stocks for 2023 here. Are investors shorting Genelux? Genelux saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 166,900 shares, an increase of 8.6% from the August 15th total of 153,700 shares. Based on an average daily trading volume, of 96,300 shares, the short-interest ratio is currently 1.7 days. Approximately 0.9% of the shares of the company are short sold. View Genelux's Short Interest. When is Genelux's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our GNLX earnings forecast. How were Genelux's earnings last quarter? Genelux Co. (NASDAQ:GNLX) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. When did Genelux IPO? (GNLX) raised $16 million in an initial public offering on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. What is Genelux's stock symbol? Genelux trades on the NASDAQ under the ticker symbol "GNLX." When did the company's lock-up period expire? Genelux's lock-up period expired on Tuesday, July 25th. Genelux had issued 2,500,000 shares in its initial public offering on January 26th. The total size of the offering was $15,000,000 based on an initial share price of $6.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Genelux's major shareholders? Genelux's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.55%), Geode Capital Management LLC (0.25%), State Street Corp (0.19%), Northern Trust Corp (0.13%), Hohimer Wealth Management LLC (0.09%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genelux's stock price today? One share of GNLX stock can currently be purchased for approximately $26.88. How much money does Genelux make? Genelux (NASDAQ:GNLX) has a market capitalization of $663.13 million and generates $11.07 million in revenue each year. How can I contact Genelux? Genelux's mailing address is 2625 Townsgate Road Suite 230, Westlake Village CA, 91361. The official website for the company is www.genelux.com. The company can be reached via phone at 805-267-9889 or via email at genelux@allelecomms.com. This page (NASDAQ:GNLX) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.